Lamivudine treatment in patients with chronic hepatitis B and cirrhosis

Bibliography

• LOK ASF, MCMAHON J: Chronic hepatitis B. Hepatology (2001) 34:1225-1241.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G: Natural history of hepatitis B. J. Hepatol. (2003) 39:50-58.
   PubMed Web of Science ®Google Scholar
• LIAW YF, TAI DI, CHU CM, CHEN TJ: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology (1988) 8:493-496.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, BROLLO L, GIUSTINA G et al.: Natural history and prognostic factors of chronic hepatitis type B. Gut (1991) 32:294-298.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G,GIUSTINA G, REALDI G, CORROCHER R, SCHALM SW: European Concerted action on viral hpatitis (EUROHEP). Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology (1997) 26:1338-1342.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, BROLLO L, ALBERTI A, PONTISSO P, GIUSTINA G, REALDI G: Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology (1988) 8:1651-1654.
   PubMed Web of Science ®Google Scholar
• COLIN JF, CAZALS-HATEM D, LORIOT MA et al.: Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology (1999) 29:1306-1310.
   PubMed Web of Science ®Google Scholar
• IKEDA K, SAITOH S, SUZUKI Y et al.: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients. J. Hepatol. (1998) 28:930-938.
   PubMed Web of Science ®Google Scholar
• SAGNELLI E, COPPOLA N, SCOLASTICO C et al.: Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C and delta viruses in patients with chronic hepatitis. Hepatology (2000) 32:1106-1110.
   PubMed Web of Science ®Google Scholar
• FUNG SK, LOK ASF: Management of patients with hepatitis B virus-induced cirrhosis. J. Hepatol. (2005) 42: S54-S64.
   PubMedGoogle Scholar
• FATTOVICH G, PANTALENA M, ZAGNI I et al.: Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterology (2002) 97:2886-2895.
   PubMed Web of Science ®Google Scholar
• REALDI G, FATTOVICH G, HADZIYANNIS S et al.: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J. Hepatol. (1994) 21:656-666.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, GIUSTINA G, SCHALM SW et al.: Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology (1995) 21:77-83.
   PubMed Web of Science ®Google Scholar
• DE JONGH, JANSSEN HLA, DE MAN RA, HOP WC, SCHALM SW, VAN BLACKENSTEIN M: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology (1992) 103:1630-1635.
   PubMed Web of Science ®Google Scholar
• BEASLEY RP, HWANG LY, LIN CC, CHIEN CS: Hepatocelllar carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 2(8256):1129-1133.
   PubMed Web of Science ®Google Scholar
• VILLENEUVE JP, DESROCHERS M, INFANTE-RIVARD C et al.: A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montréal. Gastroenterology (1994) 106:1000-1005.
   PubMed Web of Science ®Google Scholar
• MANNO M, CAMMA C, SCHEPIS F et al.: Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology (2004) 127:756-763.
   PubMed Web of Science ®Google Scholar
• CHEN CJ, YANG HI, SU J et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J. Am. Med. Assoc. (2006) 295:65-73.
   PubMed Web of Science ®Google Scholar
• SHERMAN M, BAIN V, VILLENEUVE JP et al.: The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can. J. Gastroenterol. (2004) 18:715-528.
   PubMed Web of Science ®Google Scholar
• DE FRANCHIS R, HADENGUE A, LAU G et al.: International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol. (2003) 39:S3-S25.
   PubMed Web of Science ®Google Scholar
• LIAW YF, LEUNG NW, GUAN R et al.: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Intl (2005) 25:472-489.
   PubMed Web of Science ®Google Scholar
• CHU CJ, HUSSAIN M, LOK ASF: Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology (2002) 36:1408-1415.
   PubMed Web of Science ®Google Scholar
• KEFFE EB, DIETERICH DT, HAN SHB et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin. Gastroenterol. Hepatol. (2004) 2:87-106.
   PubMedGoogle Scholar
• NIEDERAU C, HEINTGES T, LANGE S et al.: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. (1996) 334:1470-1477
   PubMedGoogle Scholar
• COOKSLEY WG, LAI M-Y, PIRATVISUTH T et al.: Treatment with peginterferon α-2a (40 kDa) (Pegasys) results in improved rates of response compared to conventional interferon in patients with HbeAg positive chronic hepatitis B, including HBV genotypes B or ‘difficult to treat’ genotype C. J. Hepatol. (2003) 38:52.
   Google Scholar
• JANSSEN HL, VAN ZONNEVELD M, SENTURK H et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 365:123-129.
   PubMed Web of Science ®Google Scholar
• LAU GK, PIRATVISUTH T, LUO KX et al.: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2005) 352:2682-2695.
   PubMed Web of Science ®Google Scholar
• HOOFNAGLE JH, DI BISCEGLIE AM, WAGGONER JG, PARK Y: Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology (1993) 104:1116-1121.
   PubMed Web of Science ®Google Scholar
• PERRILLO R, TAMBURRO C, REGENSTEIN F et al.: Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology (1995) 109:908-916.
   PubMed Web of Science ®Google Scholar
• PERRILLO RP, SCHIFF ER, DAVIS GL et al.: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. (1990) 323:295-301.
   PubMed Web of Science ®Google Scholar
• COOKSLEY WG, PIRATVISUTH T, LEE SD et al.:.Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. (2003) 10:298-305.
   PubMed Web of Science ®Google Scholar
• LAI CL, CHIEN RN, LEUNG NW et al.: A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. (1998) 339:61-68.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, SCHIFF ER, WRIGHT TL et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. (1999) 341:1256-1263.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ et al.: Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 124:105-117.
   PubMed Web of Science ®Google Scholar
• ALLEN MI, DESLAURIERS M, ANDREWS W et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology (1998) 27:1670-1677.
   PubMed Web of Science ®Google Scholar
• LEUNG NW, LAI CL, CHANG TT et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 33:1527-1532.
   PubMed Web of Science ®Google Scholar
• LIAW YF, LEUNG NW, CHANG TT et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology (2000) 119:172-180.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS S, TASSOPOULOS N, TING-TSUNG C et al.: Long-term adefovir dipivoxil treatment with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. Hepatology (2005) 42:754A.
   Google Scholar
• PERRILLO R, HANN HW, MUTIMER D et al.: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology (2004) 126:81-90.
   PubMed Web of Science ®Google Scholar
• SCHIFF E, LAI CL, HADZIYANNIS S et al.: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003): 38:1419-1427.
   PubMed Web of Science ®Google Scholar
• GISH R, CHANG T, HADZIYANNIS S et al.: Entecavir is superior to lamivudine in reducing hepatitis B DNA in patients with chronic hepatitis B infection. J. Hepatol. (2004) 40:A428.
   Google Scholar
• CHANG TT, GISH RG, DE MAN R et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2006) 354:1001-1010.
   PubMed Web of Science ®Google Scholar
• LAI CL, ROSMAWATI M, LAO J et al.: Entecavir is superior to lamivudine in reducing hepatitis B DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 123:1831-1838.
   PubMed Web of Science ®Google Scholar
• LAI CL, SHOUVAL D, LOK AS et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2006) 354:1011-1020.
   PubMed Web of Science ®Google Scholar
• TENNEY DJ, LEVINE SM, ROSE RE et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. (2004) 48:3498-3507.
   PubMed Web of Science ®Google Scholar
• JOHNSON MA, MOORE KH, YUEN GJ, BYE A, PAKES GE: Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. (1999) 36:41-66.
   PubMed Web of Science ®Google Scholar
• TASSOPOULOS NC, VOLPES R, PASTORE G et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology (1999) 29:889-896.
   PubMed Web of Science ®Google Scholar
• LIAW YF, SUNG JJ, CHOW WC et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. (2004) 351:1521-1531.
   PubMed Web of Science ®Google Scholar
• VILLENEUVE JP, CONDREAY LD, WILLEMS B et al.: Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 31:207-210.
   PubMed Web of Science ®Google Scholar
• KAPOOR D, GUPTAN RC,WAKIL SM et al.: Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J. Hepatol. (2000) 33:308-312.
   PubMed Web of Science ®Google Scholar
• YAO FY, BASS NM: Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J. Hepatol. (2000) 33:307.
   Google Scholar
• YAO FY, TERRAULT NA, FREISE C, MASLOW L, BASS NM: Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated chohor. Hepatology (2001) 34:411-416.
   PubMed Web of Science ®Google Scholar
• SPONSELLER CA, BACON BR, DIBISCEGLIE AM: Clinical improvement in patients with decompensated liver diseas caused by hepatitis B after treatment with lamivudine. Liver Transpl. (2000) 6:715-720.
   PubMedGoogle Scholar
• PERRILLO RP, WRIGHT T, RAKELA J et al.: A multicenter United-State – Canadian Trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology (2001): 33:424-432.
   PubMed Web of Science ®Google Scholar
• FONTANA RJ, HANN HW, PERRILLO RP et al.: Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology (2002) 123:719-727.
   PubMed Web of Science ®Google Scholar
• FONTANA RJ, KEEFE EB, CAREY W et al.: Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. (2002) 8:433-439.
   PubMed Web of Science ®Google Scholar
• HANN HWL, FONTANA RJ, WRIGHT T et al.: A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. (2003) 9:49-56.
   PubMedGoogle Scholar
• TSENG PL, LU SN, TUNG HD, WNAG JH, CHANGCHIEN CS, LEE CM: Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J. Viral Hep. (2005) 12:386-392.
   PubMedGoogle Scholar
• NIKOLAIDIS N, VASSILIADIS T, GIOULEME O et al.: Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin. Transplant. (2005) 19:321-326.
   PubMedGoogle Scholar
• ANDREONE P, BISELLI M, GRAMENZI A et al.: Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver translantation. Transplantation (2002) 74:1119-1124.
   PubMedGoogle Scholar
• MANALAKOPOULOS S, KARATAPANIS S, ELEFSINIOTIS J et al.: Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am. J. Gastroenterol. (2004) 99:57-63.
   PubMedGoogle Scholar
• MELEGARI M, SCAGLIONI PP, WANDS JR: Hepatitis B virus mutants associated with 3TC and famciclovir administration and replication defective. Hepatology (1998) 27:628-633.
   PubMed Web of Science ®Google Scholar
• LAI CL, DIENSTAG J, SCHIFF E et al.: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. (2003) 36:687-696.
   PubMed Web of Science ®Google Scholar
• LAMPERTICO P, VIGANO M, ROMEO R, IAVARONE M, DEL E, COLOMBO M: Long-term outcome of hepatitis B in lamivudine-resistant cirrhotic patients. J. Hepatol. (2002) 36:S1.
   PubMedGoogle Scholar
• JOHNSON MA, MOORE KHP, YUEN GJ, BYE A, PAKES GE: Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. (1999) 36:41-66.
   PubMed Web of Science ®Google Scholar
• LAMPERTICO P, VIGANO M, MANENTI E, IAVARONE M, LUNGHI G, COLOMBO M: Adefovir rapidly suppresses hepatitis B in HbeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (2005) 42:1414-1419.
   PubMed Web of Science ®Google Scholar
• FUNG SK, CHAE HB, FONTANA RJ et al.: Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. (2006) 44:283-290.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD: The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology (2000) 32:866-867.
   PubMedGoogle Scholar